Medulloblastoma Management

Subspecialty: Neuro-oncology

Type: Clinical Summary

Medulloblastoma is the most common malignant pediatric brain tumor driven by distinct developmental signaling pathways and heterogeneous genetic alterations; this review summarizes the molecular subgroup framework (WNT, SHH, Group 3, Group 4), candidate biomarkers, and evolving targeted and immunotherapeutic options alongside current surgery-, radiation- and chemotherapy-based standards. It emphasizes subgroup-specific biology, prognostic markers such as CTNNB1, TP53, MYC/MYCN and chromosome 6 monosomy, and how these inform risk stratification and selection for de-escalation or escalation stra…

Source Papers

Molecular stratifications, biomarker candidates and new therapeutic options in current medulloblastoma treatment approaches (2020)
Medulloblastoma. Nature Reviews Disease Primers (2019)
Medulloblastoma therapy: Consensus treatment recommendations from SIOP-Europe and the European Reference Network. (2025)